Novartis in new deal on Opdivo combinations

6 June 2017

Novartis (NOVN: VX) and US drugmaker Bristol-Myers Squibb (NYSE: BMY) have announced a new collaboration expanding upon existing investigations of Opdivo (nivolumab) combinations with the Swiss pharma giant’s investigational and marketed therapies.

They will investigate combinations with Mekinist (trametinib), a MEK inhibitor that formed part of a product exchange between Novartis and UK pharma major GlaxoSmithKline (LSE: GSK) in 2015.

It will be tested in combinations with Opdivo (nivolumab) alone and with a third drug, Yervoy (ipilimumab), which also belongs to B-MS, as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK